title: Advanced bronchioloalveolar carcinoma: a phase II trial of paclitaxel by 96-hour infusion (SWOG 9714): a Southwest Oncology Group study.
abstract: BACKGROUND
  There are no published prospective trials of chemotherapy for advanced bronchioloalveolar carcinoma (BAC), a subtype of non-small-cell lung cancer for which there is no current standard therapy. This phase II study assesses the efficacy and toxicity of 96-h paclitaxel in chemotherapy-naive patients with advanced BAC.
  
  
  METHODS
  Patients with histologically confirmed stage IIIB (with pleural effusion) or stage IV BAC were eligible. Treatment consisted of paclitaxel 35 mg/m2/24 h continuously infused over 96 h (days 1-4) every 21 days for up to six courses.
  
  
  RESULTS
  A total of 58 eligible patients were enrolled. The objective response rate was 14% (all partial responses, 9% confirmed); 40% of patients demonstrated stable disease. The median progression-free and overall survivals were 5 and 12 months, respectively. Grade 3 or greater toxicities included neutropenia/granulocytopenia (43%), febrile neutropenia (12%), infection (22%), and stomatitis/pharyngitis (10%); there were five treatment-related deaths.
  
  
  CONCLUSIONS
  S9714 represents the first prospective multi-institutional cooperative group trial focusing on treatment outcomes in BAC. Studies targeting this population are feasible, and while first-line paclitaxel administered as a prolonged infusion is active in this setting, toxicities limits the utility of this regimen. S9714 serves as a historical control for BAC patients against which future therapeutic approaches can be compared.
authors.affiliation: Swedish Cancer Institute/Puget Sound Oncology Consortium, Seattle, WA 98104, USA. howard.west@swedish.org
authors.forename: H L
authors.initials: HL
authors.lastname: West
authors.forename: J J
authors.initials: JJ
authors.lastname: Crowley
authors.forename: R B
authors.initials: RB
authors.lastname: Vance
authors.forename: W A
authors.initials: WA
authors.lastname: Franklin
authors.forename: R B
authors.initials: RB
authors.lastname: Livingston
authors.forename: S R
authors.initials: SR
authors.lastname: Dakhil
authors.forename: J K
authors.initials: JK
authors.lastname: Giguere
authors.forename: S E
authors.initials: SE
authors.lastname: Rivkin
authors.forename: M
authors.initials: M
authors.lastname: Kraut
authors.forename: K
authors.initials: K
authors.lastname: Chansky
authors.forename: D R
authors.initials: DR
authors.lastname: Gandara
mesh_terms: D002282:Adenocarcinoma, Bronchiolo-Alveolar / Q000188:drug therapy*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D018450:Disease Progression; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D017239:Paclitaxel / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D016019:Survival Analysis
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D017239:Paclitaxel